These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27109575)

  • 1. Advances Towards The Discovery of GPR55 Ligands.
    Morales P; Jagerovic N
    Curr Med Chem; 2016; 23(20):2087-100. PubMed ID: 27109575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
    Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
    J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
    Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
    J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.
    Morales P; Whyte LS; Chicharro R; Gómez-Cañas M; Pazos MR; Goya P; Irving AJ; Fernández-Ruiz J; Ross RA; Jagerovic N
    J Med Chem; 2016 Mar; 59(5):1840-53. PubMed ID: 26789378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
    Anavi-Goffer S; Irving AJ; Ross RA
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR55: a new promising target for metabolism?
    Tudurí E; Imbernon M; Hernández-Bautista RJ; Tojo M; Fernø J; Diéguez C; Nogueiras R
    J Mol Endocrinol; 2017 Apr; 58(3):R191-R202. PubMed ID: 28196832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.
    Yrjölä S; Parkkari T; Navia-Paldanius D; Laitinen T; Kaczor AA; Kokkola T; Adusei-Mensah F; Savinainen JR; Laitinen JT; Poso A; Alexander A; Penman J; Stott L; Anskat M; Irving AJ; Nevalainen TJ
    Eur J Med Chem; 2016 Jan; 107():119-32. PubMed ID: 26575458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling.
    Ruz-Maldonado I; Liu B; Atanes P; Pingitore A; Huang GC; Choudhary P; Persaud SJ
    Cell Mol Life Sci; 2020 Nov; 77(22):4709-4723. PubMed ID: 31925452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.
    Kotsikorou E; Madrigal KE; Hurst DP; Sharir H; Lynch DL; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak L; Abood ME; Reggio PH
    Biochemistry; 2011 Jun; 50(25):5633-47. PubMed ID: 21534610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
    Yang H; Zhou J; Lehmann C
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human serum albumin: A modulator of cannabinoid drugs.
    Leboffe L; di Masi A; Trezza V; Polticelli F; Ascenzi P
    IUBMB Life; 2017 Nov; 69(11):834-840. PubMed ID: 28976704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
    Chiba T; Ueno S; Obara Y; Nakahata N
    J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.
    Kotsikorou E; Sharir H; Shore DM; Hurst DP; Lynch DL; Madrigal KE; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak LS; Croatt MP; Abood ME; Reggio PH
    Biochemistry; 2013 Dec; 52(52):9456-69. PubMed ID: 24274581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors.
    Gasperi V; Dainese E; Oddi S; Sabatucci A; Maccarrone M
    Curr Med Chem; 2013; 20(1):64-78. PubMed ID: 23151004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells.
    Chiurchiù V; Lanuti M; De Bardi M; Battistini L; Maccarrone M
    Int Immunol; 2015 Mar; 27(3):153-60. PubMed ID: 25344934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.
    Lingerfelt MA; Zhao P; Sharir HP; Hurst DP; Reggio PH; Abood ME
    Biochemistry; 2017 Jan; 56(3):473-486. PubMed ID: 28005346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
    Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
    J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.